Exact Mass: 336.9582

Oxapyrazon

C12H8BrN3O4 (336.9698)

Pyrrolomycin I

C12H7Cl4NO2 (336.9231)

MLS000833764

C11H13Cl2N3OS2 (336.9877)

Bio5G8

C12H7Cl2F2NO2S (336.9543)

Lissoclinotoxin B

C10H11NO2S5 (336.9393)

2-Bromo-6,8-dihydroxy-7-propyl-9H-pyrrolo[2,1-b][1,3]benzoxazine-9-one

C14H12BrNO4 (336.995)

4-[(2-methoxycarbonyl-5-thiophen-2-ylthiophen-3-yl)amino]-4-oxobut-2-enoic acid

C14H11NO5S2 (337.0079)

4-(2,3-dichlorophenyl)-5,7-dihydro-2-methyl-5-oxo-Furo[3,4-b]pyridine-3-carboxylic acid

C15H9Cl2NO4 (336.9909)

HTS 01037

C14H11NO5S2 (337.0079)

HTS01037 is an inhibitor of fatty acid binding; and a competitive antagonist of protein-protein interactions mediated by AFABP/aP2 with a Ki of 0.67 μM.

2,4-Dichloro-5-(1-piperidinylsulfonyl)benzoic acid

C12H13Cl2NO4S (336.9942)

3-FLUORO-2-IODOPHENYL N,N-DIETHYLCARBAMATE

C11H13FINO2 (336.9975)

tetrasodium,2-(1,2-dicarboxylatoethylamino)butanedioate

C8H7NNa4O8 (336.9762)

4-{[3-(Trifluoromethyl)pyridin-2-yl]oxy}benzenesulfonyl chloride

C12H7ClF3NO3S (336.9787)

tert-Butyl (2-fluoro-4-iodophenyl)carbamate

C11H13FINO2 (336.9975)

5-(2-CHLORO-6-METHYLPYRIMIDIN-4-YL)-4-(4-CHLOROPHENYL)-4H-1,2,4-TRIAZOLE-3-THIOL

C13H9Cl2N5S (336.9956)

ethyl 3-bromo-7-(trifluoromethyl)imidazo[1,2-a]pyrimidine-6-carboxylate

C10H7BrF3N3O2 (336.9674)

1-BROMO-2-NITRO-4,5-DI(TRIFLUOROMETHYL)BENZENE

C8H2BrF6NO2 (336.9173)

ETHYL 5-BROMO-3-(2-CARBOXY-VINYL)-1H-INDOLE-2-CARBOXYLATE

C14H12BrNO4 (336.995)

5-Bromo-3-methoxy-2-(pyridin-4-ylmethoxy)benzoic acid

C14H12BrNO4 (336.995)

tert-Butyl (4-fluoro-2-iodophenyl)carbamate

C11H13FINO2 (336.9975)

BIS(TRICYCLOHEXYLPHOSPHINE)-3-PHENYL-1H-INDEN-1-YLIDENERUTHENIUM(II)DICHLORIDE

C12H7ClF3NO3S (336.9787)

5-Bromo-N-(4-methoxybenzyl)-3-nitropyridin-2-amine

C13H12BrN3O3 (337.0062)

Methyl 2-(5-iodo-3-nitropyridin-2-ylamino)acetate

C8H8IN3O4 (336.956)

Neodymium acetate,Neodymium(III) acetate hydrate

C6H11NdO7 (336.9582)

1-ACETYL-5-BROMO-2,3-DIHYDRO-1H-INDOLE-7-SULFONYLCHLORIDE

C10H9BrClNO3S (336.9175)

6-chloro-N-cyclopentyl-5-iodo-2-methylpyrimidin-4-amine

C10H13ClIN3 (336.9843)

4-(4-BROMOPHENYLTHIO)-3-NITROBENZALDEHYDE

C13H8BrNO3S (336.9408)

2,3-Dideoxy-5-iodocytidine

C9H12IN3O3 (336.9923)

2-BroMo-3,5-Bis (trifluoroMethyl) nitrobenzene

C8H2BrF6NO2 (336.9173)

ethyl 2-(broMoMethyl)-8-cyano-7-MethoxyiMidazo[1,2-a]pyridine-3-carboxylate

C13H12BrN3O3 (337.0062)

2-AMino-3-hydroxy-2-(hydroxyMethyl)propyl Phosphate BariuM Salt

C4H10BaNO6P (336.9298)

1-(4-(5-Bromopyridin-2-yl)piperazin-1-yl)-2,2,2-trifluoroethanone

C11H11BrF3N3O (337.0038)

(5r)-3-(3-fluoro-4-iodophenyl)-5-hydroxymethyloxazolidin-2-one

C10H9FINO3 (336.9611)

5-(3-IODOPROPOXY)-2-NITROBENZYL ALCOHOL

C10H12INO4 (336.9811)

Clodanolene

C14H9Cl2N3O3 (337.0021)

C78281 - Agent Affecting Musculoskeletal System > C29696 - Muscle Relaxant

S-(Methylmercury)-L-Cysteine

C4H9HgNO2S (337.006)

S-methylmercury-L-cysteine

C4H9HgNO2S (337.006)

2-N,6-O-disulfo-alpha-D-glucosamine

C6H11NO11S2-2 (336.9774)

(L-cysteinato-kappaS~3~)(methyl)mercury

C4H9HgNO2S (337.006)

2-N,3-O-disulfo-alpha-D-glucosamine

C6H11NO11S2-2 (336.9774)

N,3-O-disulfo-D-glucosamine

C6H11NO11S2-2 (336.9774)

N2-,6-disulfo-D-glucosamine

C6H11NO11S2-2 (336.9774)

(E)-4-[(2-methoxycarbonyl-5-thiophen-2-ylthiophen-3-yl)amino]-4-oxobut-2-enoic acid

C14H11NO5S2 (337.0079)

HTS01037 is an inhibitor of fatty acid binding; and a competitive antagonist of protein-protein interactions mediated by AFABP/aP2 with a Ki of 0.67 μM.

2-[(2,4-Dichlorophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole

C14H9Cl2N3OS (336.9843)

2-N,6-O-disulfonato-D-glucosamine(2-)

C6H11NO11S2-2 (336.9774)

2,3-dichloro-5-(3,5-dichloro-2-methoxybenzoyl)-1h-pyrrole

C12H7Cl4NO2 (336.9231)

6-methoxy-8h,9h,10h,11h-[1,2,3,4,5]pentathiepino[6,7-f]isoquinolin-7-ol

C10H11NO2S5 (336.9393)